Bringing clinical trials to patients – rather than the reverse – could be the key to improving recruitment into studies and making them faster, cheaper and more likely to succe
As specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers are scrutinising the economic value of new treatments more
In an effort to control healthcare costs, provide healthcare to the uninsured and underinsured, and improve health outcomes, there has been growing interest among politicians and the public